Akums Drugs & Pharma Intrinsic Value
AKUMS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹234.08 | ₹187.26 - ₹280.90 | -48.5% | EPS: ₹10.64, Sector P/E: 22x |
| Book Value Method | asset | ₹1136.88 | ₹1023.19 - ₹1250.57 | +150.0% | Book Value/Share: ₹988.39, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹909.50 | ₹818.55 - ₹1000.45 | +100.0% | Revenue/Share: ₹1354.84, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹909.50 | ₹818.55 - ₹1000.45 | +100.0% | EBITDA: ₹508.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1136.88 | ₹909.50 - ₹1364.26 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹136.42 | ₹122.78 - ₹150.06 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹164.39 | ₹147.95 - ₹180.83 | -63.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹554.84 | ₹499.36 - ₹610.32 | +22.0% | ROE: 5.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹486.44 | ₹437.80 - ₹535.08 | +7.0% | EPS: ₹10.64, BVPS: ₹988.39 |
Want to compare with current market value? Check AKUMS share price latest .
Valuation Comparison Chart
AKUMS Intrinsic Value Analysis
What is the intrinsic value of AKUMS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Akums Drugs & Pharma (AKUMS) is ₹554.84 (median value). With the current market price of ₹454.75, this represents a +22.0% variance from our estimated fair value.
The valuation range spans from ₹136.42 to ₹1136.88, indicating ₹136.42 - ₹1136.88.
Is AKUMS undervalued or overvalued?
Based on our multi-method analysis, Akums Drugs & Pharma (AKUMS) appears to be trading below calculated value by approximately 22.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.58 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.34 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 5.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.02x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Akums Drugs & Pharma
Additional stock information and data for AKUMS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹465 Cr | ₹191 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹498 Cr | ₹333 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹177 Cr | ₹25 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹32 Cr | ₹-86 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹135 Cr | ₹81 Cr | Positive Free Cash Flow | 8/10 |